Duodenal switch achieved greater excess body weight loss at 2 years compared to gastric bypass in superobese patients (79% vs 67%; P<0.01), alongside superior comorbidity control.
Cohort (n=78,951)
Yes
Does biliopancreatic diversion/duodenal switch improve weight loss and comorbidity control compared to gastric bypass in patients with morbid obesity?
Duodenal switch offers superior weight loss and comorbidity resolution compared to gastric bypass, especially for superobese patients, though it carries higher early perioperative risks.
Absolute Event Rate: 79% vs 67%
p-value: p=<.01
OBJECTIVE: To compare the outcomes of a large cohort undergoing biliopancreatic diversion/duodenal switch (DS) vs gastric bypass (GB). DESIGN: Retrospective review of the Bariatric Outcomes Longitudinal Database from 2007 to 2010. All inpatient and outpatient follow-up data were analyzed. SETTING: Multicenter database. PATIENTS: Patients undergoing primary DS were compared with a concurrent cohort undergoing GB. MAIN OUTCOME MEASURES: The main outcome measures were (1) weight loss; (2) control of comorbidities including diabetes mellitus, hypertension, and sleep apnea; and (3) failure to achieve at least 50% excess body weight loss. RESULTS: One thousand five hundred forty-five patients underwent DS and 77 406 underwent GB, with a mean preoperative body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 52 and 48, respectively (P 50) revealed significantly greater percentage of excess body weight loss in the DS group at 2 years (79% vs 67%; P < .01). Comorbidity control of diabetes, hypertension, and sleep apnea were all superior with the DS (all P < .05). The risk of weight loss failure was significantly reduced with DS vs GB for all patients, with a greater reduction in the BMI more than 50 subgroup. CONCLUSIONS: The DS is a less commonly used bariatric operation, with higher early risks compared with GB. However, the DS achieved better weight and comorbidity control, with even more pronounced benefits among the superobese.
Nelson et al. (Sat,) conducted a cohort in Morbid obesity (n=78,951). Biliopancreatic diversion/duodenal switch vs. Gastric bypass was evaluated on Excess body weight loss at 2 years in the superobese subgroup (BMI >50) (p=<.01). Duodenal switch achieved greater excess body weight loss at 2 years compared to gastric bypass in superobese patients (79% vs 67%; P<0.01), alongside superior comorbidity control.